N/A N=41 Neurogenic Inflammation in Diabetes
Diabetes Mellitus · Polyneuropathies · Arthropathy, Neurogenic
Primary: Induration Size as a Response to Intracutaneous Candida Albicans. — 4; 6; 5; 4 millimeters — p=0.84
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=44 Reversing Diabetic Peripheral Neuropathy Through Exercise
Peripheral Neuropathy · Diabetes
Primary: Body Mass Index (BMI) — 30.7 kg/m^2
N/A N=116 Peripheral Nerve Stimulation(PNS) for Subacromial Impingement Syndrome(SIS)
Shoulder Pain · Shoulder Impingement Syndrome · Shoulder Tendinitis
Primary: Change in - Short Form (SF) Question 3 (BPI-SF3) — 6.90; 7.05; 3.58; 3.96 units on a scale
N/A N=10 Effect Of Mesenchymal Stem Cells Transfusion on the Diabetic Peripheral Neuropathy Patients .
Diabetic Peripheral Neuropathy
Primary: Measurement of b-FGF, v-EGF MEASURED BY ELISA — 30.2; 55.4; 30.3; 428.7 pg/ml — p=0.005
N/A N=140 Effect of Exercise and Surgical Weight Loss on Polyneuropathy
Polyneuropathies · Obesity · Bariatric Surgery Candidate
Primary: Intraepidermal Nerve Fiber Density (IENFD) at the Proximal Thigh — 11.9; 12.7; 9.8; 11 fibers/mm — p=0.15
Phase 4 N=121 Pregabalin Treatment Of Peripheral Neuropathic Pain Associated With Diabetic Peripheral NeP (DPN), Postherpetic Neuralgia (PHN), HIV-related NeP (HIV), and Chemotherapy Induced NeP
Diabetic Peripheral Neuropathic Pain (DPN) · Postherpetic Neuralgia (PHN) · HIV-related Neuropathic Pain (HIV)
Primary: Change From Baseline to End of Treatment (EOT) in Weekly Mean Pain Score on the Daily Pain Rating Scale (DPRS) — -3.8 scores on scale — p=< 0.0001
Phase 3 N=256 Efficacy Study Measuring the Impact of Pregabalin on Peripheral Neuropathic Pain.
Neuropathic Pain
Primary: Neuropathic Pain in Subjects With Peripheral Neuropathic Pain Conditions During the Double-blind Phase — 2.84; 3.62 score on scale — p=0.0018
Phase 2 N=132 Topiramate for Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome (CSPN)
Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome
Primary: Intraepidermal Nerve Fiber Density (IENFD) — -0.6064; -0.396 fibers/mm/year (52 weeks)
N/A N=34 Lidocaine for Diabetic Peripheral Neuropathy
Diabetes · Peripheral Neuropathy · Pain
Primary: Change in Spontaneous Pain at 60-120 Minutes After Lidocaine Infusion Initiated (Assessed on 0-10 NRS) — 33; 51 percentage of pain change from baseline — p=0.03
N/A N=101 Effect of Exercise on Gait and Balance in Peripheral Neuropathy
Diabetic Neuropathies · Peripheral Nerve Diseases · Peripheral Nervous System Diseases
Primary: Gait and Balance Measures — 51.3; 51.2; 52.3 units on a scale
N/A N=13 BlueWind Medical Reprieve System for the Treatment of PNP
Peripheral Neuropathy
Primary: The Incidence of System and/or Procedure Related Serious Adverse Events (SAEs). — 1 Participants
N/A N=44 Corneal Nerves Function and Structure
Diabetic Peripheral Neuropathy
Primary: Cornea Sensitivity — 0.177; 0.293 time ratio of eyelids closed vs. open — p=<0.001
Phase 4 N=402 Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations
Cryptogenic Sensory Polyneuropathy
Primary: Co-Primary Measures: Percent of Patients With at Least a 50% Decrease in Likert Pain Scale From Baseline to Week 12 Follow Up and Percent of Patients That Quit — 34; 29…
Phase 3 N=240 Pregabalin Peripheral Neuropathic Pain Study
Diabetic Neuropathies · Neuralgia
Primary: Daily Pain Rating Scale (DPRS)- Mean Pain Score (ITT Population) — 4.63; 5.13 score on scale — p=0.049
N/A N=61 Chemotherapy Induced Peripheral Neuropathy. Could Physical Therapy Help Treat Symptoms?
Breast Cancer · Peripheral Neuropathy, Secondary to Drugs or Chemicals
Primary: Percentage of Participants With 'Pain' or 'no Pain' as Measured by the Numeric Pain Rating Scale — 30; 49; 70; 51 percentage of participants — p=0.053
N/A N=161 Symptom Management Efficacy Study to Reduce Distal Neuropathic Pain
Neuropathic Pain · HIV Neuropathy · HIV/AIDS
Primary: Gracely Pain Scale (GPS) — -2.51; -1.96; -2.38; -0.99 GPS pain score on a scale
N/A N=166 Electrical Stimulation for the Treatment of Back Pain Using Peripheral Nerve Stimulation (PNS)
Back Pain · Low Back Pain
Primary: Number of Subjects That Experienced ≥30% Reduction in Average Low Back Pain Intensity — 58 Participants
N/A N=120 Treatment of Critical Illness Polyneuromyopathy
Acute Respiratory Failure
Primary: The Primary Outcome Variable for This Study Will be the Short Form of the Continuous Scale Physical Functional Performance Test (CS-PFP) Called the PFP-10 — 19.0; 20.9…
Phase 2 N=18 L-Serine Supplementation in Hereditary Sensory Neuropathy Type 1
Hereditary Sensory and Autonomic Neuropathy Type I
Primary: Charcot Marie Tooth Neuropathy Score — 25.67; 20.22 scores on a scale
Phase 3 N=665 Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
Diabetic Neuropathy, Painful
Primary: Change From Single-Blind Baseline in Mean Pain Score at Week 19 During Double-Blind Phase — 6.8; 6.7; -3.9; -3.5 units on a scale — p=0.1221
N/A N=22 Nociceptive Pain Fiber Response
Painful Peripheral Diabetic Neuropathy
Primary: Changes in Small Nerve Fiber Density by Assessment of a Skin Biopsy Comparing Baseline to Day 60 — .1; .1 nerve fibers / mm squared
N/A N=26 Immunotherapy of the Paraneoplastic Syndromes
Paraneoplastic Syndromes
Primary: Survival of Patients With Paraneoplastic Disease Who Are Treated With Tacrolimus — 48 months
N/A N=23 Peripheral Nerve Stimulation for Shoulder Pain: Dose Response
Stroke · Shoulder Pain
Primary: Brief Pain Inventory (BPI)- Short Form (SF) Question 3 (BPI-SF3) — 5.6; 6; 5.67; 6.5 score on a scale
Phase 2 N=45 Evaluation of Nicotinamide Riboside in Prevention of Small Fiber Axon Degeneration and Promotion of Nerve Regeneration
Small Fiber Neuropathy
Primary: Denervation of Skin — 0.1; 0.1 percent change — p=0.33
N/A N=19 MRI Diffusion Tensor Tractography to Monitor Peripheral Nerve Recovery After Severe Crush or Cut/Repair Nerve Injury
Nerve Injury
Primary: Michigan Hand Questionnaire (MHQ) in TPNI Subjects Post Surgery — 33; 83; 5; 75 score on a scale
Phase 3 N=542 Placebo-controlled Safety and Efficacy Study of Pregabalin in Subjects With Post-traumatic Peripheral Neuropathic Pain
Neuropathic Pain
Primary: Baseline Mean Pain Score — 6.41; 6.54 units on a scale
N/A N=16 Postoperative Peripheral Nerve Stimulation for Management of Post-amputation Pain
Phantom Limb Pain · Postoperative Pain · Neuroma
Primary: Average Phantom Limb Pain (PLP) Score — 4.1; 3.1; 2.2; 3.0 score on a scale
N/A N=1,270 Balancing Treatment Outcomes and Medication Burden Among Patients With Symptomatic Diabetic Peripheral Neuropathy
Diabetic Peripheral Neuropathy
Primary: Change in Patient Quality of Life at Baseline and 8 Months — 0.66; 0.65; 0.68; 0.68 units on a scale
N/A N=22 Combined Brain and Peripheral Nerve Stimulation for Stroke
Stroke
Primary: Active Range of Motion of Wrist Extension in the Paretic Side — 37.8; 38; 37.2; 38 degrees
N/A N=14 Electrical Stimulation in Diabetic Peripheral Neuropathy
NMES · Control
Primary: Nerve Conduction Speed (Common Peroneal Nerve) — 33.93; 44.1; 41.63; 44.13 m/sec